Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Genentech has struck research partnerships with three biotech companies. The first is with Sosei Heptares to develop small molecules that target G protein–coupled receptors. Sosei could receive up to $26 million in near-term payments and over $1 billion in milestones. The second is with Skyhawk Therapeutics to develop small molecules that alter RNA splicing in cancer and neurodegenerative diseases. Skyhawk could earn more than $2 billion in payments. The third deal is with Convelo Therapeutics to discover drugs that regenerate myelin in the nervous system to treat diseases like multiple sclerosis. Terms were not disclosed.
This article has been sent to the following recipient: